{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:22:50Z","timestamp":1790706170307,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jaci.2019.06.016","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T07:03:35Z","timestamp":1564988615000},"page":"353-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Pruritus in allergy and immunology"],"prefix":"10.1016","volume":"144","author":[{"given":"Ting-Lin B.","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2019.06.016_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000319862","article-title":"Prevalence of chronic pruritus in Germany: results of a cross-sectional study\u00a0in a sample working population of 11,730","volume":"221","author":"St\u00e4nder","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.jaci.2019.06.016_bib2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2340\/00015555-1159","article-title":"Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study","volume":"91","author":"Matterne","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2019.06.016_bib3","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-018-8685-0","article-title":"The unique molecular signatures of contact dermatitis and implications for treatment","volume":"56","author":"Leonard","year":"2019","journal-title":"Clin Rev Allergy Immuno"},{"key":"10.1016\/j.jaci.2019.06.016_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2018.05.005","article-title":"Cytokine modulation of atopic itch","volume":"54","author":"Trier","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib6","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.it.2018.10.001","article-title":"The itch\u2013scratch cycle: a neuroimmune perspective","volume":"39","author":"Mack","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib7","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1111\/febs.14465","article-title":"Interactions of the immune and sensory nervous systems in atopy","volume":"285","author":"Oetjen","year":"2018","journal-title":"FEBS J"},{"key":"10.1016\/j.jaci.2019.06.016_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.det.2018.02.014","article-title":"Immunomodulating agents as antipruritics","volume":"36","author":"Erickson","year":"2018","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2019.06.016_bib9","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/nature06029","article-title":"A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord","volume":"448","author":"Sun","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2019.06.016_bib10","author":"McNeil"},{"key":"10.1016\/j.jaci.2019.06.016_bib11","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.cell.2009.11.034","article-title":"Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus","volume":"139","author":"Liu","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2019.06.016_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1744-8069-10-4","article-title":"B-type natriuretic peptide is neither itch-specific nor functions upstream of the GRP-GRPR signaling pathway","volume":"10","author":"Liu","year":"2014","journal-title":"Mol Pain"},{"key":"10.1016\/j.jaci.2019.06.016_bib13","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1126\/science.1233765","article-title":"The cells and circuitry for itch responses in mice","volume":"340","author":"Mishra","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jaci.2019.06.016_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4168\/aair.2017.9.6.477","article-title":"Chronic spontaneous urticaria: pathogenesis and treatment considerations","volume":"9","author":"Kaplan","year":"2017","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaci.2019.06.016_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1710-1492-10-24","article-title":"Leukotriene receptor antagonists for chronic urticaria: a systematic review","volume":"10","author":"de Silva","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib16","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/jid.2008.55","article-title":"Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies","volume":"128","author":"Eckman","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2019.06.016_bib17","series-title":"Antihistamines and itch","first-page":"257","author":"Thurmond","year":"2015"},{"key":"10.1016\/j.jaci.2019.06.016_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuropharm.2015.05.004","article-title":"The histamine H4-receptor and the central and peripheral nervous system: a critical analysis of the literature","volume":"106","author":"Schneider","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jaci.2019.06.016_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.114.215749","article-title":"The histamine H\u2084 receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects","volume":"350","author":"Kollmeier","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaci.2019.06.016_bib20","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jaci.2006.04.005","article-title":"Anti-IgE as a mast cell\u2013stabilizing therapeutic agent","volume":"117","author":"Chang","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.06.016_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2019.06.016_bib23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fc\u03b5RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib24","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria","volume":"139","author":"Gericke","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib25","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1172\/JCI85538","article-title":"Different activation signals induce distinct mast cell degranulation strategies","volume":"126","author":"Gaudenzio","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2019.06.016_bib26","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.immuni.2019.03.013","article-title":"Activation of mast-cell-expressed Mas-related G-protein-coupled receptors drives non-histaminergic itch","volume":"50","author":"Meixiong","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2019.06.016_bib27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2019.06.016_bib28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/jdv.13599","article-title":"ETFAD\/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients","volume":"30","author":"Wollenberg","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2019.06.016_bib29","first-page":"47","article-title":"Peripheral blood eosinophilia in atopic dermatitis","volume":"16","author":"Jenerowicz","year":"2007","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"10.1016\/j.jaci.2019.06.016_bib30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12016-011-8252-4","article-title":"IgE, mast cells, and eosinophils in atopic dermatitis","volume":"41","author":"Liu","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/jid.2014.401","article-title":"Innate Lymphoid Cells in the Skin","volume":"135","author":"Kim","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2019.06.016_bib32","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron\u2013expressed IL-31 receptor mediates T helper cell\u2013dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib33","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti\u2013interleukin-31 receptor A\u00a0antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.06.016_bib34","doi-asserted-by":"crossref","first-page":"E7572","DOI":"10.1073\/pnas.1606608113","article-title":"IL-33\/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy","volume":"113","author":"Liu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2019.06.016_bib35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2019.06.016_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1401","article-title":"Pharmacokinetics, safety, and tolerability of tezepelumab (AMG 157) in healthy and atopic dermatitis adult subjects","author":"Parnes","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaci.2019.06.016_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2019.06.016_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti\u2013IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib40","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.06.016_bib41","doi-asserted-by":"crossref","first-page":"e24137","DOI":"10.4161\/jkst.24137","article-title":"The involvement of the JAK-STAT signaling pathway\u00a0in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao","year":"2013","journal-title":"JAK-STAT"},{"key":"10.1016\/j.jaci.2019.06.016_bib42","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2019.06.016_bib43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.06.016_bib44","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjd.16014","article-title":"Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study","volume":"178","author":"Nakagawa","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2019.06.016_bib45","doi-asserted-by":"crossref","first-page":"AB128","DOI":"10.1016\/j.jaci.2018.12.387","article-title":"Ruxolitinib cream suppresses Th2 inflammation in adult patients with atopic dermatitis","volume":"143","author":"Owens","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl","key":"10.1016\/j.jaci.2019.06.016_bib46","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.anai.2018.09.063","article-title":"Upadacitinib effect on pruritus in moderate-to-severe atopic dermatitis; from a phase 2b randomized, placebo-controlled trial","volume":"121","author":"Beck","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib47","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.06.016_bib48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.det.2018.02.003","article-title":"Prurigo nodularis and its management","volume":"36","author":"Zeidler","year":"2018","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2019.06.016_bib49","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-3083.2012.04481.x","article-title":"Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients","volume":"27","author":"Iking","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2019.06.016_bib50","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1046\/j.1365-4362.1998.00507.x","article-title":"Prurigo nodularis in HIV-infected individuals","volume":"37","author":"Matthews","year":"1998","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2019.06.016_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1529-8019.2008.00168.x","article-title":"Prurigo nodularis and lichen simplex chronicus","volume":"21","author":"Lotti","year":"2008","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2019.06.016_bib52","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1600-0560.2009.01484.x","article-title":"Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients","volume":"37","author":"Weigelt","year":"2010","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaci.2019.06.016_bib53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib54","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1034\/j.1600-0560.2000.027007359.x","article-title":"CGRP-immunoreactive nerves in prurigo nodularis\u2014an exploration of neurogenic inflammation","volume":"27","author":"Liang","year":"2000","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaci.2019.06.016_bib55","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jdermsci.2010.03.020","article-title":"Low density\u00a0of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis","volume":"58","author":"Haas","year":"2010","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2019.06.016_bib56","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1001\/jamadermatol.2018.3912","article-title":"Dupilumab treatment for generalized prurigo nodularis","volume":"155","author":"Beck","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2019.06.016_bib57","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaad.2019.01.052","article-title":"Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial","volume":"80","author":"St\u00e4nder","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.06.016_bib58","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.sder.2011.04.002","article-title":"Pruritus in elderly patients-eruptions of senescence","volume":"30","author":"Berger","year":"2011","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaci.2019.06.016_bib59","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jaad.2015.11.029","article-title":"Immune dysregulation underlies a subset of patients with chronic idiopathic pruritus","volume":"74","author":"Xu","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.06.016_bib60","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaad.2018.02.030","article-title":"Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial","volume":"78","author":"Yosipovitch","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2019.06.016_bib61","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.iac.2016.08.014","article-title":"Allergic contact dermatitis","volume":"37","author":"Kostner","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2019.06.016_bib62","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1567-5769(01)00173-4","article-title":"Allergic contact dermatitis","volume":"2","author":"Kimber","year":"2002","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaci.2019.06.016_bib63","first-page":"249","article-title":"Diagnosis and management of contact dermatitis","volume":"82","author":"Usatine","year":"2010","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jaci.2019.06.016_bib64","series-title":"Dermatology","article-title":"Allergic contact dermatitis","author":"Mowad","year":"2012"},{"key":"10.1016\/j.jaci.2019.06.016_bib65","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/jid.2013.351","article-title":"Histamine H4 receptor antagonists ineffective against itch and skin inflammation in atopic dermatitis mouse model","volume":"134","author":"Kamo","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2019.06.016_bib66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0167-5699(83)90046-4","article-title":"Delayed-type hypersensitivity: activation of mast cells by antigen-specific T-cell factors initiates the cascade of cellular interactions","volume":"4","author":"Askenase","year":"1983","journal-title":"Immunol Today"},{"key":"10.1016\/j.jaci.2019.06.016_bib67","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2011.03.028","article-title":"Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens","volume":"34","author":"Dudeck","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2019.06.016_bib68","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.4049\/jimmunol.1600236","article-title":"Mast cells limit the exacerbation of chronic allergic contact dermatitis in response to repeated allergen exposure","volume":"197","author":"Gimenez-Rivera","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib69","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/ni1503","article-title":"Mast cell\u2013derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B","volume":"8","author":"Grimbaldeston","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2019.06.016_bib70","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1016\/j.celrep.2019.02.089","article-title":"Nppb neurons are sensors of mast cell-induced itch","volume":"26","author":"Solinski","year":"2019","journal-title":"Cell Rep"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674919308280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674919308280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:20:58Z","timestamp":1758792058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674919308280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0091674919308280"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2019.06.016","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pruritus in allergy and immunology","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2019.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}